NSI-566RSC cell grafts ameliorate stroke-induced motor deficits.

<p>Motor performance was measured by EBST (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0091408#pone-0091408-g001" target="_blank">Figure 1</a>). All animals displayed normal motor behavior at Baseline (i.e., prior to stroke). At day 7 post-stroke, all animals exhibited 100% biased swing behaviors, indicating that all animals received successful stroke. At 14 days post-stroke onwards, dose-dependent and timing-dependent effects of the treatment were recognized, in that the improvement in behavioral performance was in the order of high dose to zero dose as follows: 20,000 cells/µl (D) >10,000 cells/µl (C) >5,000 cells/µl (B)>vehicle infusion only (A). In addition, over time there was a trend of better improvement, with the most significant improvement seen at 56 days post-stroke. *significant <0.05 vs. other treatment groups within time point; ^#significant <0.05 vs. other time points.